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A B S T R A C T
The growing interest on polymeric delivery systems for pulmonary administration of drugs anticipates a more
direct and eﬃcient treatment of diseases such as tuberculosis (TB) that uses the pulmonary route as the natural
route of infection. Polymeric microparticles or nano-in-microparticles oﬀer target delivery of drugs to the lungs
and the potential to control and sustain drug release within TB infected macrophages improving the eﬃciency of
the anti-TB treatment and reducing side eﬀects. In a dry powder form these inhalable delivery systems have
increased stability and prolonged storage time without requiring refrigeration, besides being cost-eﬀective and
patient convenient.
Thus, this review aims to compile the recent innovations of inhalable polymeric dry powder systems for the
delivery of anti-TB drugs exploring the methods of production, aerodynamic characterization and the eﬃcacy of
targeted drug delivery systems using in vitro and in vivo models of the disease. Advanced knowledge and pro-
mising outcomes of these systems are anticipated to simplify and revolutionize the pulmonary drug delivery and
to contribute towards more eﬀective anti-TB treatments.
1. Introduction
Tuberculosis (TB), caused by infections with Mycobacterium tu-
berculosis (Mtb), is an infectious disease of enormous public health
impact. TB is an airborne disease initiated by the inhalation of infected
droplets that travel the upper respiratory tract and bronchi, being
deposited in the lower airways. Here, Mtb is thought to be recognized
and phagocytosed by macrophages, speciﬁcally alveolar macrophages.
In the majority of cases, this initial interaction between Mtb and im-
mune cells results in the development of a host protective response
capable of eliminating the invading pathogen. In some cases however,
the immune response does not eliminate the infection thereby resulting
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in a spectrum of disease with diﬀerent phenotypes and clinical mani-
festations [1]. It is estimated that approximately one-third of the world
population has contacted with Mtb and part of this population is likely
latently infected [2]. Although these individuals do not show signs or
symptoms of TB, as the bacteria proliferation is under immune control,
they have a 10% increased risk of progressing into active TB during
their life time being therefore important reservoirs for transmission [3].
The current anti-TB therapy protocols comprise of a six-month
combination course of rifampicin (R), isoniazid (I), pyrazinamide (Z)
and ethambutol (E), which are ﬁrst-line anti-TB drugs. All four drugs
are taken during the ﬁrst two months of the treatment following a
period of four months where only rifampicin and isoniazid are taken.
Although the success rate of this regimen has been estimated to be over
85% [2], the full length of treatment is crucial for the eﬀective and
complete eradication of the pathogen. However, the incorrect use of
anti-TB drugs or the use of ineﬀective drug formulations such as single
drug regimen, poor quality medicines or inappropriate storage condi-
tions and premature treatment interruption due to the long duration of
the therapeutic regimen and the associated toxic side eﬀects, lead to
drug resistance [2].
Treatment for drug resistant strains, which include rifampicin-re-
sistant TB (RR-TB), multidrug-resistant TB (MDR-TB) and extensively
drug-resistant TB (XDR-TB) is longer (up to 2 years) and requires more
expensive and more toxic drugs with treatment success rates lower than
54% [2].
Therefore, in addition to classical drug discovery strategies, new
approaches are urgently needed to get a faster, more eﬃcient and less
harmful treatment. In this regard, the development of novel therapies
aiming at pulmonary delivery and drug targeting to the site of infection
could be a promising solution to allow a sustainable and controlled
release of medicines with therapeutic action, while decreasing the do-
sage and frequency of conventional chemotherapy and minimizing side
eﬀects. Moreover, these approaches may lead to a higher eﬃciency of
the treatment and to a higher patient compliance, minimizing the risk
of therapy failure and the development of drug resistant strains.
2. Delivery of anti-tuberculosis drugs to the lungs
2.1. Advantages of the pulmonary route
Despite the natural barriers to prevent invasion of unwanted air-
borne particles or living entities, such as airway geometry, humidity,
mucociliary clearance and resident populations of macrophages, the
lungs are constantly challenged with infectious agents, including Mtb,
which make these air-ﬁlled organs an attractive target for drug delivery
strategies as it provides direct access to the infection site. Delivery
systems for TB treatment through the pulmonary route present ad-
vantages when compared to the conventional oral and injectable routes.
These include drug delivery directly to the infected area, increasing
local drug concentration which will impact in bacterial burden and
reduce the systemic dosage of the drug [4–13]. Additionally, inhalable
systems avoid unwanted side eﬀects often caused by drug metabolism
in the gastrointestinal tract before the drug reaches the systemic cir-
culation [4–13]. Unlike the injectable route, inhalation is a pain free
and self-administrable delivery means favoring patient convenience
and compliance to the treatment.
2.2. Particulate carriers as inhalable delivery systems
Pure drug formulations are typically burst released in the lungs and
rapidly undergo unspeciﬁc distribution [5,14–18]. In order to achieve a
more eﬃcient solution, therapeutic agents can be formulated into
particulate carrier systems such as microparticles, nanoparticles, lipo-
somes, micelles or dendrimers. Such systems allow protection of drugs
from direct contact with the lung tissue, avoiding early degradation,
preclude rapid clearance from the body and assist the control and
sustain release of drugs over long periods of time. Particulate carriers
also reduce drug toxicity, circumvent undesirable physicochemical
properties of the drugs (e.g. low water solubility) and improve drug up-
take by macrophages [19].
In recent years the advantages of inhalable particulate carrier sys-
tems have been allied to the beneﬁts of dry powder formulations to be
delivered by dry powder inhalers (DPIs) for an improved drug delivery
system. Dry powder formulations have improved stability as a result of
its dry form, do not require refrigeration and allow longer storage
periods. Formulations are often combined with pharmaceutically sui-
table excipients such as lactose, leucine, mannitol or trehalose to im-
prove processing and aerodynamic properties [20,21]. DPIs are pro-
pellant free, portable, easy to use and cost-eﬀective devices. Moreover,
DPIs are activated by the inspiration eﬀort of patients, allowing a rapid
and higher dose administration and a more eﬃcient pulmonary drug
deposition [22,23]. Thus, DPIs are currently considered the most con-
venient and suitable alternative for inhaling anti-TB drugs [24].
2.3. Design and features of inhalable particulate systems
Medicinal particles are designed and developed so their deposition
in the respiratory tract can be predicted rather precisely (Fig. 1). The
Fig. 1. Schematic representation of the particle deposition within the upper or lower airways considering their dimensions and the type of carrier systems used for
their delivery.
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behavior of inhaled particles and their deposition depend of several
parameters including particle dimensions, density, shape, composition,
concentration, surface properties such as particle charge and the
breathing pattern (air ﬂow) of the individual [13,25].
The aerodynamic diameter is an important parameter aﬀecting the
pulmonary trajectory and depends on both particle dimension and
density. Particles with an aerodynamic diameter in the range 1–5 μm
are deposited in the lower airways, which is a desirable location for
anti-TB drugs [13,26–28]. On the other hand, particles larger than 5 μm
undergo deposition in the upper regions, such as the nasopharynx and
they are consequently swallowed, while particles smaller than 1 μm are
likely to be exhaled or retained in the alveoli if transported by a carrier
system [13,26,29]. After reaching the lower airways, particulate sys-
tems are likely to be either phagocytized by alveolar macrophages,
adhere to the lung tissue or enter the blood circulation via lung vascular
tree. Another potential destination is the entrapment of these particles
within the granulomas which are compact and organized aggregates of
immune cells where Mtb persists [30,31].
2.4. Types of microparticulate dry powder systems
Liposomes, micelles and polymeric particles have been developed as
inhalable dry powder particulate systems aiming at anti-TB drug de-
livery strategies. Liposomes and micelles studies were reviewed else-
where [32,33]. Polymeric particles oﬀer great opportunities in target
drug delivery and controlled and sustained release of drugs. The pos-
sibility of surface modiﬁcation of polymeric particles can give rise to
systems with a great diversity of physicochemical properties and, if
desired, favor a more eﬃcient targeting approach [34]. Additionally,
the production of polymeric particles is considerably more cost-eﬀec-
tive than lipidic systems.
Polymeric particles include microparticles and nano-in-micro-
particles and these can further be divided into nanocomposites (also
referred as nano-embedded microparticles) and porous nanoaggregate
particles (PNAPs) (Fig. 2). Nano-in-microparticle systems have been
developed to utilize nanoparticulate systems, often exhaled from the
lungs, into successful inhalable drug carrier systems (Fig. 1). In nano-
composites, drug loaded nanoparticles are incorporated in a micronized
sugar matrix (e.g. lactose, mannitol, leucine, maltodextrin) to form
micro-scaled particles of 1–5 μm. These nanocomposites can then be
decomposed into nanoparticles in the lower airways, since the sugar
moiety is soluble in the lung lining ﬂuid. On the other hand, PNAPs
consist of spherical nanoaggregates at the micron-size level that also re-
disperse into the elementary nanoparticles in the lung lining ﬂuid.
A considerable focus has been given to synthetic polymers poly
(lactide-co-glycolide) (PLGA) and polylactide (PLA) due to their bio-
compatible and biodegradable properties, non-toxicity [35–37] and to
the ability to encapsulate hydrophobic anti-TB drugs. Synthetic poly-
mers also beneﬁt from high purity products and batch-to-batch uni-
formity. However, more recently, the trend for dry powder production
has been shifted towards the use of natural polymers such as chitosan,
gelatin or guar gum due to their abundance and availability in nature,
cost eﬀectiveness and the fact that these raw materials require a
minimal use of organic solvents to be processed. Also, combinations of
polymers have been tested to merge properties of the polymers involved
in order to obtain more eﬃcient delivery systems.
2.5. Techniques used to develop polymeric microparticulate dry powders
A brief explanation on the most common production techniques to
prepare inhalable polymeric drug delivery microparticulate and nano-
in-microparticulate systems is described in Table 1. The techniques
presented in this table have shown to produce carrier systems with
suitable aerodynamic diameters using a wide range of synthetic and
natural based polymers.
Emulsion followed by solvent evaporation is commonly used to
produce microparticles, in particular PLGA microparticles, however
these are produced with a relatively wide size distribution [38]. Makino
et al. have used this technique with a Shirasu porous glass (SPG)
membrane to formulate microparticles with lower size dispersion
[39,40]. In order to overcome the low yield of this process, a premix
membrane emulsiﬁcation method was used to prepare monodispersed
PLGA microparticles [41,42]. Alternatively to SPG membrane emulsi-
ﬁcation, an adjuvant strategy based on glass beads facilitated stirring,
improved the homogeneity of PLGA microparticles produced by the
emulsion/solvent evaporation method [43]. Although emulsion/sol-
vent evaporation is often used to produce anti-TB drug loaded micro-
particles, it is labor intensive and not practicable for large production,
which can limit translational strategies into therapies.
Inhalable microparticles and nano-in-microparticles were success-
fully obtained using the spray-drying (SD) technique [38,44–46], the
most used technique for production of inhalable dry powders for anti-
TB delivery. SD is a simple, fast and versatile technique that can be used
with diﬀerent spray nozzles. For instance, rifampicin dihydrate micro-
crystals were coated with PLGA and/or PLA by SD with a three-ﬂuid
spray nozzle producing core-shell microcapsules with the appropriate
aerodynamic properties to reach the alveoli and with controlled release
properties not achieved by using only rifampicin dihydrate micro-
crystals [14,15]. Due to the existence of three independent channels,
one for the core (drug), one for the shell (polymer) and the other for the
Fig. 2. Developed inhalable dry powder systems for anti-TB drug delivery based on polymeric particles.
M.S. Miranda et al. Materials Science & Engineering C xxx (xxxx) xxx–xxx
3
atomizing gas, the process can be done in a single step.
Nanocomposites containing rifampicin-PLGA nanoparticles and
mannitol have also been prepared in a one-step approach using a four-
ﬂuid nozzle spray drier [53]. In this technique two liquid and two gas
passages allowed the drug and the carrier to be prepared in diﬀerent
solvents avoiding the limitations associated to using a common solvent
as in the traditional two ﬂuid spray-drier.
Spray-drying can also be combined with techniques such as anti-
solvent precipitation and ionotropic gelation that are oriented to na-
noparticle production, to fabricate nano-in-microparticulate systems.
Inhalable guar gum nanoparticles were prepared using the precipitation
technique with ethanol as anti-solvent [50]. Chitosan and alginate na-
noparticles have been prepared by the ionotropic gelation, a method
based on the complexation between oppositely charged species namely
chitosan and tripolyphosphate anion or calcium cation and alginate
[51,52,54]. The physical cross-linking by electrostatic interactions
avoids toxic reagents used in the chemical cross-linking such as glu-
taraldeyde.
The supercritical technique has also been proposed for the pro-
duction of inhalable polymeric microparticles. Patomchaiviwat et al.
prepared rifampicin loaded PLA microparticles, in a size range suitable
for lower airways deposition, using a supercritical anti-solvent process
[49]. Supercritical anti-solvent is a quite recent and barely explored
technique for anti-TB drug delivery. Although it is a single step process
this technology is expensive and labor intensive and requires deeper
investigation to assess its full potential for anti-TB drug delivery.
2.6. Carrier systems oriented for macrophage targeting
Phagocytosis of drug carrier systems by macrophages especially by
infected macrophages is a very interesting approach leading to the in-
ternalization of these systems, and to an intracellular inﬂux of the drug
in the phagosome, where the bacilli reside, which could result in a more
eﬃcient anti-TB approach.
Among the physical properties, the size of the particulate carrier
system is one of the most important characteristics aﬀecting up-take via
phagocytosis (Fig. 3) [55].
Phagocytosis ranged particles (1–6 μm) enter the macrophage and
can potentially deliver larger amounts of anti-TB drugs directly to the
infection than oral or injected drug doses [56]. Particle shape also plays
an important role in the up-take process as the local shape determines
the initial contact with macrophages and their phagocytic fate [57].
Using shape-switching particles it was shown that elliptical disks have
potential to mitigate phagocytosis, however when they switched their
shape into spheres they were internalized by macrophages [58]. In
relation to surface charge an increase up-take was observed when PLGA
microparticles were coated with cationic polymer polyethylenimine
relative to uncoated ones [43]. Furthermore, harder and non-porous
particles are more eﬃciently taken up than soft and porous particles
and hydrophobic and insoluble particles are more easily opsonized and
this fact increases the probability of recognition by alveolar macro-
phages [55]. The chemical composition of the particle is also a sig-
niﬁcant feature for macrophage response. PLGA microparticles pre-
pared with diﬀerent proportions of lactide and glycolide and with
diﬀerent PLGA molecular weights result in diﬀerent interactions with
alveolar macrophages [59]. The presence of mannose moiety in the
structure of polymers such as guar gum and mannan results in higher
up-take by macrophages [51,60,61].
The carrier surface can be functionalized to incorporate ligands that
target macrophage surface receptors in a process that is known as active
targeting. Mannosylated gelatin microparticles have been developed to
target macrophage mannose membrane receptor [62]. Other ligands
including carbohydrate binding receptors such as galactose, β-glucan,
N-acetylglycosamine and folic acid have been explored for macrophage
targeting aiming at a wide range of diseases [63]. However, their po-
tential towards therapeutic TB strategies requires further investigation.
3. Emerging inhalable polymeric dry powders
The main outcomes on recent works on dry powder microparticles
and nano-in-microparticles for anti-TB drug delivery envisioning the
improvement of inhalable administration of therapeutic drugs are
compiled in Tables 2 and 3, respectively.
Table 1
Summary of the techniques most often used in the preparation of polymeric microparticulate and nano-in-microparticulate systems for anti-TB pulmonary drug
delivery.
Technique Brief explanation of working principle Advantages of the process Disadvantages of the process Ref.
Emulsion/solvent
evaporation
An organic solvent is used to dissolve the drug and polymer
followed by the addition of an aqueous solution containing a
dispersion stabilizer. The emulsion is sonicated followed by solvent
evaporation.
Preserves the physicochemical
characteristics of the polymer
Relatively wide size
distribution of microparticles
Use of organic solvents
Diﬃcult to scale up
Two step process
[38,47]
Spray-drying (SD) Transforms a feed in the ﬂuid state into a dried particulate form by
spraying into a hot drying medium.
Simple, fast, one-step, continuous
and reproducible production process
No ﬁnal drying step
High versatility
Easy to scale up
Higher drug incorporation when
compared with other techniques
Higher polydispersity when
compared with other
techniques
Expensive equipment and
operation conditions
[38,48]
Supercritical anti-
solvent
The drug and polymer are dissolved in an organic solution and the
supercritical ﬂuid (e.g. SCO2) acts as an anti-solvent promoting the
precipitation of the microparticles.
Single-step process Use of organic solvents
diﬃcult to scale up
Expensive
Labour intensive
[49]
Anti-solvent
Precipitation/SD
Drop-wise addition of an anti-solvent (e.g. ethanol, diethyl ether)/
drug solution to a polymer solution under rapid mixing. The drug
loaded nanoparticles are next spray dried with excipients to form
nanocomposites.
Low cost Two-step process
Use of organic solvents
Diﬃcult to scale-up
[50]
Ionotropic gelation/SD Drop-wise addition of cross-linking agent (e.g. TPP, CaCl2) into
polymer solution containing drug and under stirring. The drug
loaded micro- or nano- particles are next spray dried with or
without excipients to form microparticles or nanocomposites.
Avoids the use of toxic reagents used
in the chemical cross-linking
Two step process
Diﬃcult to scale-up
[51,52]
Legend: SCO2: supercritical carbon dioxide; SD: Spray-drying; TPP: tripolyphospate.
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3.1. Polymeric microparticles
3.1.1. Poly(lactide-co-glycolide) (PLGA)
The production of inhalable dry powder polymeric microparticles
for pulmonary anti-TB drug delivery began with rifampicin loaded
PLGA (R-PLGA) microparticles prepared by O'Hara and Hickey in 2000
[38]. In the meanwhile, the role of PLGA properties such as molecular
weight and monomer composition have been studied to more accu-
rately predict the loading eﬃciency and release rate of rifampicin [39].
Moreover, particles size [40], polymer content [65], pH of release
medium [39] and presence of pulmonary surfactants in the release
medium [29,48] have also been assessed for their inﬂuence in ri-
fampicin release proﬁle.
R-PLGA microparticles have shown to be eﬀectively phagocytosed
by NR8383 macrophage cells and exerted a more potent bactericidal
eﬀect on Mycobacterium bovis Bacillus Calmette-Guérin infected
NR8383 macrophage cells than a rifampicin solution [39,47,56,81–85].
These results were supported with in vivo studies, where the insuﬄation
of R-PLGA microparticles to Wistar rats lead to 10 times greater amount
of rifampicin in alveolar macrophages than a rifampicin insuﬄated
powder [84]. Using Sprague-Dawley rats infected with Mtb Kurono
strain as a model, intratracheal administration of R-PLGA micro-
particles was shown to be more eﬃcient in killing the intracellular
bacilli and on the prevention of granuloma formation in the lungs than
a rifampicin powder [85]. The eﬃcacy of inhalable R-PLGA micro-
particles was also assessed in Mtb (H37Rv)-infected guinea pigs by in-
suﬄation and/or nebulization into the lungs [18,86]. The bacterial
burden and lung damage was signiﬁcantly reduced in the presence of
the microparticles and the eﬀect of a single dose of R-PLGA micro-
particles was found to be comparable to that after treatment for 20
consecutive days with micronized rifampicin suspensions [87].
3.1.2. Polylactide (PLA)
Inhalable PLA microparticles were developed to incorporate both
rifampicin and isoniazid as a promising carrier for anti-TB drug delivery
[4]. These microparticles were up-taken by J774 murine macrophages
and led to higher intracellular drug concentrations in comparison with
equivalent amounts of drugs given in the culture medium. Mtb H37Ra
infected J774 macrophages responded to rifampicin and isoniazid
loaded PLA microparticles with a classical activation macrophages re-
sponse not observed with drug solutions alone [45]. Additionally, ri-
fampicin and isoniazid loaded PLA micropaticles administered to rats
via intratracheal instillation and inhalation resulted in higher
intracellular drug concentrations than oral and intracardiac injection
delivery of soluble drugs [4]. These studies conﬁrm that phagocytosis of
particulate polymeric drug carriers results in the delivery of higher
amounts of drugs to TB infected macrophages than those obtained from
diﬀusive uptake of drugs dissolved in body ﬂuids.
In another work by Muttil et al. rifabutin instead of rifampicin was
loaded in inhalable PLA microparticles mainly because rifampicin is
incompatible with isoniazid in organic solutions [5]. These rifabutin
and isoniazid loaded PLA microparticles when administered to mice by
inhalation or intra-tracheal instillation targeted macrophages as in-
tracellular drug concentrations were found to be about 20 higher than
serum concentrations. This approach also resulted in higher drug con-
centrations in macrophages than oral, intra-cardiac injection and even
intra-tracheal instillation of free drug solutions [5,88,89]. Inhalation of
rifabutin and isoniazid loaded PLA microparticles by Rhesus macaques
also evidenced an eﬃcient targeting of alveolar macrophages and lung
tissue sparing non-target sites such as blood, liver and kidneys from the
toxic drugs [90]. The ability of rifabutin and isoniazid loaded PLA
microparticles to sustain higher levels of drugs in the cytosol of mac-
rophages and for longer periods in comparison with soluble drugs
highlight their eﬃcacy in stimulating innate biological responses
evoking a bactericidal action including induction of free radicals,
changes in membrane potential and apoptosis [91–93].
3.1.3. Poly-caprolactone (PCL)
Although not so explored in inhaled anti-TB dry powders as PLGA
and PLA, PCL has also been used to design microparticles suitable for
pulmonary drug delivery [16,70]. In vitro and in vivo studies have
shown that inhalable isoniazid loaded PCL (I-PCL) microparticles lead
to a higher uptake as well as to a higher generation of mycobactericidal
nitric oxide (NO) relative to isoniazid microparticles. This could be due
to the hydrophobic nature of PCL favoring alveolar macrophages up-
take and is an indication of the superior eﬃcacy of PCL microparticles
in comparison with isoniazid microparticles. As expected, intratracheal
administration of I-PCL microparticles to rats lead to higher isoniazid
accumulation in the lungs and less systemic drug availability and less
hepatotoxicity eﬀects over oral isoniazid administration. Thus, I-PCL
microparticles prepared as inhalable dry powders may improve TB
treatment eﬃcacy and reduce hepatotoxicity which in turn will lead to
a reduced period of treatment and improvement of patient compliance.
3.1.4. Hydroxyl propyl methyl cellulose (HPMC)
HPMC has been used as drug carrier [71,94] and inhalable dry
Fig. 3. Physico-chemical properties of microparticulate systems undergoing phagocytosis by alveolar macrophages.
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powder formulations have been prepared with rifampicin [71] and
ethionamide [72], an anti-TB drug used in the treatment of MDR-TB.
Although these studies suggest the suitability of HPMC formulations for
reaching the lower airways, in vitro and in vivo studies are still needed to
validate their application in TB treatment.
3.1.5. Chitosan
The mucoadhesive properties of chitosan are related to its cationic
charge and makes chitosan more likely to adhere to the lungs and
prolong drug release [95,96]. Moreover, chitosan particles are able to
interact with the mannose receptors of macrophages, which results in
increased phagocytosis [97]. Chitosan microparticles have been for-
mulated with several anti-TB drugs including rifampicin [71,73,74],
rifabutin [74], isoniazid [75,76], oﬂoxacin [60] and ethionamide [72]
for pulmonary delivery. Cross-linked isoniazid loaded chitosan micro-
particles allowed a more sustained isoniazid release with 50% release in
6 h in comparison to non-crosslinked microparticles with over 50%
released in 1 h [76]. Both non- and crosslinked microparticles can be of
interest for TB treatment because in the ﬁrst phase of the treatment,
which is more intense, non-crosslinked microparticles may rapidly re-
lease isoniazid into the alveoli whereas cross-linked microparticles can
be used in a second phase of the treatment (maintenance phase). Also
the mucoadhesive properties of both non- and cross-linked chitosan
microparticles were conﬁrmed in vitro and in vivo, which can increase
their time of residence in the lungs after inhalation. Moreover, both
chitosan microparticles showed some toxic eﬀect on murine peritoneal
macrophages (J-774.1) which was microparticle concentration depen-
dent (0.01–1mg/mL) but no toxic eﬀect on alveolar macrophages
(AMJ2-C11). The activation of AMJ2-C11 cells with chitosan micro-
particles resulted in increased amounts of inﬂammatory cytokines:
TNF-α, IL-1β, IL-6 in AMJ2-C11 cells in comparison to free isoniazid
solubilized in culture medium.
As for other chitosan drug loaded microparticles, chitosan micro-
particles loaded with rifampicin and rifabutin showed to be less toxic to
the lungs than free drug administration [74].
3.1.6. Gelatin
Although gelatin is not so deeply studied for pulmonary delivery,
gelatin microparticles loaded with isoniazid have been produced to
actively target alveolar macrophages [62]. As macrophages hold man-
nose membrane receptors, mannosylated gelatin microparticles ex-
hibited signiﬁcantly higher intracellular concentration of isoniazid than
the non-mannosylated. Additionally, intratracheal administration of
isoniazid loaded mannosylated gelatin microparticles to rats allowed
achieving isoniazid therapeutic concentration in plasma. These results
suggest the potential application of macrophage targeting in TB treat-
ment that should be more deeply investigated.
3.1.7. Hyaluronic acid (HA)
Hyaluronic acid (HA) has also been explored for the development of
microparticles for anti-TB pulmonary drug delivery. HA is a versatile
polysaccharide involved in the assembly of the extracellular matrix
(ECM) of numerous native tissues and has been applied in multiple
clinical procedures. Oﬂoxacin loaded HA (Ofx-HA) microparticles have
shown good aerosolization eﬃciency when combined with lactose [6].
Ofx-HA microparticles uptake by the alveolar macrophage cell line
(RAW 264.7) lead to higher oﬂoxacin concentration than from oﬂox-
acin microparticles or from an oﬂoxacin solution. Moreover, in-
tratracheal administration of Ofx-HA microparticles to rats seems to be
much more eﬀective than intravenous or oral administration of an
oﬂoxacin solution and intratracheal administration of oﬂoxacin mi-
croparticles for the treatment of TB.
3.1.8. Locust Bean Gum (LBG)
LBG is a polysaccharide composed of galactose and mannose units
with potential application for macrophage targeting. InhalableTa
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isoniazid and rifabutin loaded LBG microparticles were taken up by two
macrophage cell lines: human macrophage-diﬀerentiated THP-1 cells
and rat alveolar macrophages (NR 8383 cells) with high percentages of
phagocytosis [61]. In another study by the same group LBG micro-
particles loaded with both drugs, isoniazid and rifabutin, thus meeting
WHO requirements concerning combined TB therapy [77].
3.1.9. Combination of polymers
The idea of merging the advantageous properties of diﬀerent poly-
mers led to the development of microparticulate systems that result
from the combination of polymers such as chitosan and ethyl cellulose
[78]. Ethyl cellulose, which is a hydrophobic matrix carrier, was used
for encapsulating and sustained release of the hydrophobic drug rifa-
butin, while chitosan was envisioned to provide bio-adhesion to the
microparticles promoting pulmonary retention of the delivery system.
The produced microparticles showed sustained release due to cross-
linking with genipin and intratracheal administration to rats lead to
prolonged pulmonary retention, thus maintaining drug concentrations
at therapeutic level for at least 24 days.
Poly-lysine is a cationic polymer and the toxicity associated to its
high charge density and high molecular weight restricts its use as a drug
carrier system. Tiwari et al. coupled a low molecular weight lysine
polymer with mannose in order to reduce the toxicity of the carrier
system, having also a synergistic eﬀect on the uptake by macrophages
[62]. The lysine polymer was also conjugated with alginate to reduce the
toxicity of the system, improve drug loading eﬃciency and for a sus-
tained and controlled drug release. This mannosylated lysine conjugated
to alginate (m-LS-co-ALG) natural based carrier system was used for
pulmonary delivery of isoniazid. m-LS-co-ALG microparticles have no
signiﬁcant toxic eﬀects in rat alveolar macrophages up to a concentration
as high as 20mg/mL. Isonizaid loaded m-LS-co-ALG microparticles, in-
tratracheally administered to rats, were eﬀectively up-taken by alveolar
macrophages and prolonged the presence of isoniazid in the blood.
The most studied polymers for microparticle production for inhal-
able delivery are PLGA and PLA although natural polymers such as
chitosan have gained great interest in recent years due to their avail-
ability, cost-eﬀectiveness and resemblance to biopolymers from living
tissues. Despite chitosan being an attractive candidate for inhalable
drug delivery other natural sources should be considered and their
applicability explored. Biopolymers as collagen or chondroitin sulfate
are natural materials used for particle fabrication in biomedical appli-
cations that could be transposed and investigated for TB approaches.
Diﬀerent polymers have shown promising results in the design and
loading of anti-TB drugs in clinical use. The incorporation of anti-TB
drugs in polymer based carriers often increases the drug solubility, al-
lows the protection of the drug before reaching the target site and allows
modulating the release proﬁle of the drugs assisting a sustained release.
With very few exceptions, studies report microparticulate systems
incorporating ﬁrst line drugs. This approach is quite useful to improve
treatments eﬃciency by reducing the drug dosage (without prejudice to
their eﬀectiveness), reduction of systemic toxicity, reducing the re-
gimen period and thus contributing to the eradication of the disease.
Nevertheless, the development of polymeric dry powder delivery sys-
tems is also envisioned to contribute to anti-TB therapies when the
treatment fails. Second line drugs as capreomycin and oﬂoxacin, which
are typically more toxic that ﬁrst line drugs, could have their dosage
reduced and the parental administration replaced by the pulmonary
route favoring stability, storage and shelf life. This approach would also
favor patient compliance to the treatment and likely increase the suc-
cess rate in drug resistant-TB strategies.
3.2. Polymeric nano-in-microparticles
3.2.1. Poly(lactide-co-glycolide) (PLGA)
Rifampicin loaded PLGA nanocomposites have been produced by
Tomoda et al. to be used as an inhalation system [20,21]. The inﬂuence
of the excipient, size of primary nanoparticles, weight ratio nano-
particle:excipient and inlet temperature of the spray dryer on the
aerodynamic and decomposition properties of the nanocomposites were
investigated. Nanoparticles with dimensions of 200 nm and 400 nm,
combined with trehalose at the inlet temperatures of 70 °C and 80 °C,
respectively, were considered the most promising ones for pulmonary
delivery. These results were independent from the weight ratio nano-
particle:excipient.
Rifampicin loaded PLGA nanocomposites prepared with mannitol
(R-PLGA/MAN) were readily dispersed in culture medium and dis-
sociate to nanoparticles which are not so eﬃciently in vitro up-taken by
NR8383 cells (13.5%) as micro-sized rifampicin loaded PLGA particles
(47.1%) [53]. Conversely, intra-tracheal administration of R-PLGA/
MAN nanocomposites to rats lead to a higher rifampicin uptake (about
9.3% after 4 h) by alveolar macrophages in comparison with R-PLGA
and R/MAN microparticles which was explained by the diﬃculty to
clear the nanoparticles from the lungs.
Intratracheal insuﬄation of rifampicin-PLGA PNAPs formulations to
guinea pigs led to a prolonged presence of rifampicin in the lungs up to
8 h whereas insuﬄated rifampicin porous particles or rifampicin given
intravenously or orally showed low or no levels of rifampicin in the
lungs [28].
3.2.2. Hydroxy propyl methyl cellulose (HPMC)
PNAPs of HPMC loaded with rifampicin and isoniazid were pre-
pared with mannitol and leucine to improve yield and aerodynamic
properties of the powders [98]. 24 h after insuﬄation of the developed
PNAPs in rats, approximately 25% of drug was still in the lungs while in
the case of plain drug administration no drug was detected. Moreover,
organ distribution studies showed a lower level of drug from the de-
veloped PNAPs in the liver and kidney in comparison with plain drug
due to the controlled drug release from the PNAPs formulations.
3.2.3. Alginate
Alginate nanocomposites have been developed for pulmonary de-
livery of rifampicin and isoniazid [52]. The minimum inhibitory con-
centration (MIC) of rifampicin (0.2 ± 0.01 μg/mL) and isoniazid
(0.1 ± 0.01 μg/mL) loaded alginate nanocomposites against Mtb was
approximately 3–4 times lower than that of free rifampicin
(0.5 ± 0.01 μg/mL) and isoniazid (0.4 ± 0.01 μg/mL) solutions. De-
veloped formulations insuﬄated to mice could be detected in the lungs
for up to 8 h ensuring a localized and controlled drug delivery and
exhibited a higher rate and extent of drug uptake by lungs than by liver,
spleen and kidney.
3.2.4. Chitosan
Chitosan nanocomposites have been prepared for anti-TB pul-
monary drug delivery. Inhalable rifampicin loaded chitosan nano-
composites have shown negligible in vitro toxicity on murine J774
macrophage cells [99]. Inhalation of the developed formulation by rats
lead to a higher maximum drug concentration and a higher residence
time in the lungs (up to 24 h) in comparison with a rifampicin com-
mercial powder, explained by the sustained release of rifampicin from
the developed formulation. Moreover, only mild changes were found in
the pathology of treated lungs from the developed formulation unlike a
commercial rifampicin solution given orally that showed severe toxi-
city.
3.2.5. Guar gum
The presence of the mannose moiety in guar gum imparts a great
aﬃnity towards macrophage mannan receptors increasing macrophage
cells up-take [51]. Rifampicin and Isoniazid loaded guar gum PNAPs
insuﬄated to rats revealed a greater amount of drug in the lungs in
comparison with the liver and kidneys [50]. Moreover, unlike plain
drug administration, about 15% of the drugs from the developed for-
mulations were still detected in the lungs after 24 h, which was ascribed
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to the mucoadhesive properties of guar gum and the ability to control
the release of the drugs from the developed systems.
3.2.6. Mannan
Mannan is a linear polysaccharide of mannose subunits which could
favor speciﬁc recognition by macrophages and potentiate phagocytosis.
Inhalable rifampicin and isoniazid loaded mannan nanocomposites
have demonstrated an excellent uptake by J-774 macrophage cells and
a MIC about 15 times lower than those of rifampicin and isoniazid
solutions [51]. However, when insuﬄated to Mtb infected mice they
exhibited a low lung residence time due to their intrinsic solubility.
3.2.7. Combination of polymers
Goyal et al. prepared nanocomposites made of diﬀerent polymers
namely chitosan, guar gum, mannan and guar gum coated chitosan
nanocomposites [51]. Guar gum coated chitosan nanocomposites were
shown to be the most promising for pulmonary anti-TB drug delivery.
Guar gum coated rifampicin and isoniazid loaded chitosan nano-
composites insuﬄated to Mtb infected mice showed a prolonged re-
sidence of the drug in the lungs thereby improving the therapeutics
utility and resulted in almost 5-fold reduction of the number of bacilli
as compared to the untreated control group 45 days post administration
[51].
Although the nano-in-microparticles produced are promising for
drug delivery these particles are still less studied than microparticles for
TB treatment. The anti-TB drug loading in nano-in-microparticles is
increased over microparticles due to a greater surface area/volume
ratio of nanoparticles. Nano-in-microparticles re-disperse into the ele-
mentary nanoparticles in the lung lining ﬂuid and due to their dimen-
sions they are not cleared as fast as the microparticles, which may lead
to an increased presence in the lungs leading to a higher drug up-take
[53]. However, as referred in Section 2.5, the production of nano-in-
microparticles relies on a combination of techniques and a multi-step
production, which is labor intensive and diﬃcult to scale up.
Overall, polymeric systems either in the form of microparticles or as
nano-in-microparticles have been developed with improved function-
alities to eﬃciently transport and release the drug to the lung alveoli
and to target a resident population of macrophages. Independently of
the polymer systems and associated speciﬁcities, the advantage of using
polymeric dry powders as drug loading microparticulate system over
direct drug administration to the lungs is evident for pulmonary de-
livery and towards the treatment of TB.
It is important, however, to establish standardized models, both in
vitro and in vivo, that enable to more accurately compare the eﬀec-
tiveness and therapeutic potential of the drug loaded particulate sys-
tems developed. It is critical to study these systems in models that
mimic the transport along the human airways, considering real ther-
apeutic dosages given to human patients and the challenges involved in
the mechanisms for drug release and particle uptake in macrophages in
order to validate their application in clinics.
3.3. Targeting host cell responses
Mtb has co-evolved with humans for thousands of years and has
developed several strategies to prevent elimination by its host. Host-
mediated responses, such as activation of protective inﬂammatory
mediators, including cytokines and chemokines that induce natural
microbicidal pathways and recruit white blood cells to the infection
site, may provide an eﬃcient mean to eﬀectively eliminate Mtb and
targeting host responses has been recently explored for TB treatment.
However, a considerable disadvantage over bacteria-oriented ap-
proaches is the toxicity to the host cells, which can be overcome to a
certain extent using carrier systems.
Verma et al. explored alveolar macrophage response to NO using
PLGA microparticles containing NO donors (isosorbide mononitrate,
sodium nitroprusside or diethylenetriamine nitric oxide adduct) [102].
NO is known to possess mycobactericidal properties and indeed it is one
of the most important macrophage microbicidal mechanisms. The ad-
dition of anti-TB drugs rifabutin and isoniazid further increase the ef-
ﬁciency of the developed system [103]. Gupta et al. produced inhalable
PLGA microparticles for targeting rapamycin, which is an inducer of
autophagy, to alveolar macrophages [104]. The PLGA microparticles
containing rapamycin were less toxic to host cells and more eﬀective in
inducing the clearing of intracellular Mtb, as compared to rapamycin in
the free form. The eﬃciency of this system was also found to increase in
conjunction with inhalable rifabutin and isoniazid [105]. Other systems
of inhalable particles containing nitazoxanide, which has moderate
mycobactericidal activity and is also an inducer of autophagy in
mammalian cells, were incorporated alone or in combination with ri-
fabutin and isoniazid agents [106]. The combination of these drugs
incorporated in the polymeric microparticles cleared Mtb H37Rv from
lungs and spleen of infected mice and restored tissue architecture in
higher extent than rifabutin-isoniazid particles.
3.4. Magnetic nanoparticles for anti-TB drug therapies
Magnetic nanoparticles (MNPs) have shown potential for a wide
range of biomedical applications, including biosensing, imaging and
targeted drug delivery, as MNPs can be manipulated under the inﬂu-
ence of a magnetic ﬁeld [107,108]. MNPs have already been approved
for clinical use as contrast agents in magnetic resonance imaging (MRI)
allowing the diagnostic of several diseases. Additionally, MNPs can be
oriented and concentrated towards a given tissue location via an ex-
ternal magnetic ﬁeld actuation allowing a more eﬃcient treatment and
minimizing side eﬀects. Magnetized aerosols comprising super-
paramagnetic iron oxide nanoparticles (SPIONs) have been studied for
pulmonary delivery of drugs and genes to treat diseases of the deeper
airways [109,110]. These nanomagnetosols have shown potential to be
in vivo controlled and spatially guided in the lungs using an external
magnetic gradient ﬁeld.
Despite the promising outcomes of MNPs for pulmonary delivery
applications, few studies refer their use in inhalable dry powders for TB
treatment strategies. MNPs can be incorporated within microparticulate
systems and be part of a sophisticated imaging and guiding system for
pulmonary drug delivery purposes. Tewes et al. fabricated SPIONs-
loaded Trojan microparticles for targeting bacterial infectious pul-
monary foci upon loading with the appropriate drug [111]. This pre-
liminary study showed that the developed microparticles have good
aerodynamic properties and their deposition was found to be highly
sensitive to the actuation of an external magnetic ﬁeld. Moreover, the
drug release proﬁle can be modulated according to the treatment re-
quirements with the application of an external stationary or alternating
magnetic ﬁelds, contributing for improved treatment eﬃciency [112].
In a recent paper gelatin-based microparticles containing SPIONs were
proposed as inhalable dry-powder carriers for a candidate anti-TB drug
to be released inside alveolar macrophages [113]. The actuation of an
external alternating magnetic ﬁeld was shown to remotely trigger and
modulate the anti-TB drug release, which could contribute for im-
proved strategies for TB treatment.
4. Conclusions and future perspectives
Tuberculosis is a worldwide disseminated disease with potential to
be treated and ultimately eradicated. Current therapeutic regimens
show limitations than can be overcome with more sophisticated and
oriented approaches, such as using inhalable polymeric dry powders for
anti-TB drug delivery. These systems are quite versatile and growing
evidence suggests that they are also more eﬃcient in the drug targeting
macrophages than oral or injected drug administration and even drug
free inhalation. Moreover, dry powders show promising outcomes for
the treatment of lung diseases and with impact in the quality of life of
patients. The fact that they are easily stored, cost-eﬀective and simple
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to administer are attractive features for up-scaling and commerciali-
zation. Magnetic particles can add clinical signiﬁcance to the system as
a valuable tool to guide the system to a given location and, simulta-
neously provide a non-invasive real-time monitoring system during the
follow-up of patients after drug administration.
Moreover, the ability to target phagocytosed bacilli or the cells in-
volved in Mtb clearance is a considerable advantage to be deeper in-
vestigated aiming at personalized strategies, considering each patient
individual needs and orient the most suitable treatment not only in
terms of drug selection but also targeting a speciﬁc location (either
alveoli niche, alveoli macrophage, Mtb bacilli or the granuloma) to
better suit the patient needs.
In the future, pulmonary delivery systems can eventually combine
the administration of one or multiple pharmaceutical agents to induce
diﬀerent yet synergistic responses for instance, microbiocidal eﬀect
over Mtb and simultaneously target alveoli macrophages towards a
more eﬀective and shorter treatment regimen.
The challenge in upcoming years also resides in ﬁne tuning inhal-
able dry powder carriers focusing on their multifactorial nature and
ﬁnal application, accompanying the progress of new anti-TB formula-
tions to meet individual needs with simple yet eﬃcient drug delivery
systems to be routinely used in clinical therapies.
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